Related Experiment Videos
[Guillain-Barré syndrome]
1Department of Biochemistry, Faculty of Medicine, Tokyo Medical and Dental University.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 1, 1994
Summary
Guillain-Barré syndrome (GBS) patients often have antibodies to GM1 ganglioside after Campylobacter jejuni infection. This molecular mimicry may explain GBS development.
Area of Science:
- Neuroimmunology
- Infectious Diseases
- Molecular Mimicry
Background:
- Guillain-Barré syndrome (GBS) is an autoimmune disorder affecting the peripheral nervous system.
- Campylobacter jejuni infection is a common trigger for GBS.
- Autoantibodies against GM1 ganglioside are found in GBS patients.
Purpose of the Study:
- To investigate the association between Campylobacter jejuni serotype 19 (PEN 19) and GBS.
- To explore the role of anti-GM1 antibodies in GBS pathogenesis.
- To understand the mechanism of molecular mimicry in GBS.
Main Methods:
- Analysis of sera from GBS patients following C. jejuni infection.
- Serotyping of C. jejuni isolates.
- Investigation of autoantibody presence and targets (GM1 ganglioside).
- Assessment of anti-GM1 antibody effects on motoneuron excitability.
Main Results:
- Sera from GBS patients showed autoantibodies to GM1 ganglioside during acute illness.
- A strong association was observed between GBS and C. jejuni PEN 19.
- The lipopolysaccharide of C. jejuni PEN 19 shares structural similarity with GM1 ganglioside.
- Anti-GM1 antibodies were found to inhibit motoneuron excitability.
Conclusions:
- Molecular mimicry between C. jejuni and nerve tissue components is implicated in GBS development.
- The structural identity between bacterial lipopolysaccharide and GM1 ganglioside provides a mechanism for autoantibody generation.
- Anti-GM1 antibodies contribute to the neurological deficits seen in GBS.